Laekna, Inc. (HKG:2105)

Market Cap	5.28B
Revenue (ttm)	557.63K
Net Income (ttm)	-270.61M
Shares Out	373.62M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,571,000
Average Volume	2,815,575
Open	14.40
Previous Close	14.62
Day's Range	13.92 - 14.52
52-Week Range	3.90 - 17.78
Beta	n/a
RSI	58.61
Earnings Date	May 16, 2025

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 86
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

In 2024, Laekna's revenue was 524,000, an increase of 11.49% compared to the previous year's 470,000. Losses were -254.30 million, -31.05% less than in 2023.

Financial numbers in CNY